Trials / Terminated
TerminatedNCT04635735
Study of Ipilimumab After Stem Cell Transplantation in People With Relapsed/Refractory Multiple Myeloma
A Phase I/II Trial of Ipilimumab After CD34-Selected Allogeneic Stem Cell Transplantation for Patients With Relapsed/Refractory Multiple Myeloma
- Status
- Terminated
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 3 (actual)
- Sponsor
- Memorial Sloan Kettering Cancer Center · Academic / Other
- Sex
- All
- Age
- 21 Years – 73 Years
- Healthy volunteers
- Not accepted
Summary
This study will test the safety of ipilimumab to see what effects, if any, the drug has when used as maintenance therapy for people with relapsed/refractory multiple myeloma who have received chemotherapy and allogeneic hematopoietic stem cell transplant (AHCT). The investigators also want to find out whether giving ipilimumab after chemotherapy and AHCT is a better way to control the multiple myeloma than chemotherapy and AHCT alone.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ipilimumab | Ipilimumab 3 mg/kg every 3 weeks for 4 doses. |
Timeline
- Start date
- 2020-01-12
- Primary completion
- 2023-02-02
- Completion
- 2023-02-02
- First posted
- 2020-11-19
- Last updated
- 2023-03-23
- Results posted
- 2023-03-23
Locations
7 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04635735. Inclusion in this directory is not an endorsement.